Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 3:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Liver damage Clear all
Completed Phase 2 Interventional

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

NCT06409130
View directory record Official record
Conditions
Alcohol-related Liver Disease
Interventions
NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
29
States / cities
Chandler, Arizona • Tucson, Arizona • Lancaster, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development of a Community Engagement Activity for Advance Care Planning

NCT02575417
View directory record Official record
Conditions
Chronic Disease
Interventions
Conversation Game
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis

NCT04072822
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Anakinra and Zinc, Prednisone, Placebos
Drug
Lead sponsor
Indiana University
Other
Eligibility
21 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Phoenix, Arizona • Jacksonville, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

Compassionate Use of an Intravenous Fish Oil Emulsion in the Treatment of Liver Injury in Infants

NCT00738101
View directory record Official record
Conditions
Cholestasis, Cholestasis of Parenteral Nutrition
Interventions
Omegaven
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Days to 5 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 6, 2026, 3:34 PM EDT
Approved For Marketing No phase listed Expanded access

Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage

NCT01861834
View directory record Official record
Conditions
Cholestasis of Parenteral Nutrition
Interventions
Omegaven 10%
Drug
Lead sponsor
Georgetown University
Other
Eligibility
2 Months to 18 Years
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 6, 2026, 3:34 PM EDT
Terminated No phase listed Observational

Prospective Tumor Response Evaluation

NCT02787954
View directory record Official record
Conditions
Hepatocellular Cancer, Metastatic Liver Cancer
Interventions
TACE, Y-90, MWA, IRE
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 6, 2026, 3:34 PM EDT
Terminated Not applicable Interventional Results available

Methacetin Breath Test in Patients With Liver Disease Secondary to Heart Disease

NCT04176458
View directory record Official record
Conditions
Dilated Cardiomyopathy, Tricuspid Atresia
Interventions
Methacetin Breath Test (MBT)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Sep 6, 2026, 3:34 PM EDT
Enrolling by invitation Not applicable Interventional

Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis

NCT03032601
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
N-acetyl Cysteine
Dietary Supplement
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed No phase listed Observational

Case Control Study of Pharmacogenomic Factors Associated With Hepatocellular Injury Following Exposure to Lapaquistat Acetate

NCT00890448
View directory record Official record
Conditions
Toxicity
Interventions
Pharmacogenomic whole blood sampling
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Jacksonville, Florida • Jupiter, Florida • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Withdrawn No phase listed Observational

Evaluation of Kidney Disease in Liver Transplant Recipients

NCT00585429
View directory record Official record
Conditions
Kidney Disease, Liver Transplantation
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Adults With or Without Liver Damage

NCT05976321
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
TAK-279
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 6, 2026, 3:34 PM EDT
Withdrawn Not applicable Interventional

Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)

NCT01923376
View directory record Official record
Conditions
Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status, AMS
Interventions
Lactulose, Polyethylene Glycol 3350
Drug
Lead sponsor
New York Presbyterian Brooklyn Methodist Hospital
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional Results available

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation

NCT03342196
View directory record Official record
Conditions
Leukemia
Interventions
Melphalan, Thiotepa, Fludarabine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
1 Year to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional Results available

Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients

NCT01594385
View directory record Official record
Conditions
Open Abdomen, Abdominal Adhesions, Trauma, Wounds and Injury
Interventions
Seprafilm
Biological
Lead sponsor
Stan Stawicki
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Camden, New Jersey • Charlotte, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 6, 2026, 3:34 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

DILIN - Prospective Study

NCT00345930
View directory record Official record
Conditions
Liver Diseases
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
2 Years and older
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 2 Interventional

4-PBA: Will it Increase the Level of Alpha 1-Antitrypsin(AAT) in Persons With AAT Deficiency?

NCT00067756
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
4-PBA
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 2, 2014 · Synced Sep 6, 2026, 3:34 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.

NCT07401862
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
LY3841136
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Not applicable Interventional

L-arginine for Prevention of Kidney Damage in Liver Transplant Recipients

NCT00587418
View directory record Official record
Conditions
Liver Transplant Recipients
Interventions
L-arginine, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage

NCT02300025
View directory record Official record
Conditions
Healthy Volunteer
Interventions
cobimetinib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Sep 6, 2026, 3:34 PM EDT
Completed No phase listed Observational

Cytokines Polymorphisms and Acetaminophen Toxicity

NCT00166608
View directory record Official record
Conditions
Drug Toxicity
Interventions
Blood sampling
Procedure
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
Not listed
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Little Rock, Arkansas • Louisville, Kentucky • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Sep 6, 2026, 3:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

NCT02611505
View directory record Official record
Conditions
Hepatic Impairment, Normal Hepatic Function
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 6, 2026, 3:34 PM EDT
Completed No phase listed Observational

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

NCT04970212
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Metastatic Liver Cancer
Interventions
BioTraceIO Lite
Device
Lead sponsor
Techsomed Medical Technologies LTD
Industry
Eligibility
21 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Phoenix, Arizona • Stanford, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 6, 2026, 3:34 PM EDT
Terminated Phase 2 Interventional Results available

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT04541173
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Y-90 TARE, Atezolizumab, Bevacizumab
Other · Drug
Lead sponsor
Aiwu Ruth He, MD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 6, 2026, 3:34 PM EDT